Evoke Pharma, Inc. (EVOK)
$11.00+0.00%Close
BUYBULL · day 31
Key stats
- Market cap
- $19M
- Beta
- -0.14
- P/E (TTM)
- -10.28
- 1W
- +0.64%
- 1M
- +2.90%
- vs SPY 1W
- +1.62%
- vs SPY 1M
- +1.03%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 40
- VALUE
- 16
- GROWTH
- 32
- GARP
- 82
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-42.3%
REV YoY-
ROE-70.5%
EPS YoY-
ROA-17.4%
GROSS97
OP-34
NET-34
[VALUATION]
P/E TTM-10.28
P/E FWD6.07
SECTOR PE20.48
INDUSTRY PE19.11
P/B8.37
P/FCF-
EV/EBITDA-5.04
EV/EBIT-
PEG0.03
FCF YIELD-
RISK
INT COV-
D/E152.05
ALTMAN Z-
CURR RATIO1.27
ND/EBITDA-
BETA-0.14
Company news
FAQ
- What is LOPJLB’s current signal on EVOK?
- LOPJLB’s latest quantitative signal on Evoke Pharma, Inc. (EVOK) is BUY in a BULL regime. Signals are updated daily.
- What market regime is EVOK in?
- Evoke Pharma, Inc. (EVOK) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Evoke Pharma, Inc. (EVOK) do?
- Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associat…